Evidence map›Paper›PMID 39812351›Full record

ArticlePediatric pulmonology2025

Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.

Vito Terlizzi, Cristina Fevola, Santiago Presti, Laura Claut, Maura Ambroni, Maria Adelaide Calderazzo, Irene Esposito, Benedetta Fabrizzi, Giuseppina Leonetti, Mariangela Lombardo and 16 more

Abstract read
In one paragraph

Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cystic Fibrosis Year in Review 2024.Pediatric pulmonology · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Vito TerlizziDepartment of Paediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Florence, Italy.ORCID http://orcid.org/0000-0003-1106-4424
Cristina FevolaDepartment of Paediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Florence, Italy.
Santiago PrestiDepartment of Paediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Florence, Italy.ORCID http://orcid.org/0000-0002-4879-5418
Laura ClautDepartment of Pediatrics, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Maura AmbroniCystic Fibrosis Center, Ospedale Maurizio Bufalini, Cesena, Ospedale M.Bufalini Cesena, ASL Romagna, Italy.
Maria Adelaide CalderazzoCystic Fibrosis Regional Reference Center, Ospedale Giovanni Paolo II Lamezia Terme, ASP Catanzaro, Italy.
Irene EspositoPediatric Cystic Fibrosis Center, Ospedale Infantile Regina Margherita, Torino, Italy.
Benedetta FabrizziMother‑Child Department, Cystic Fibrosis Regional Reference Center, United Hospitals, Ancona, Italy.
Giuseppina LeonettiPediatric Cystic Fibrosis Center, Azienda Universitaria Ospedaliera Consorziale Policlinico, Bari, Italy.
Mariangela LombardoCystic fibrosis Center, University Hospital AOU G. Martino, Messina, Italy.
Massimo MaschioInstitute for Maternal and Child-IRCCS Burlo Garofolo, Trieste, Italy.
Nicola PalladinoCystic Fibrosis Center of Umbria Region, Gubbio-Gualdo Tadino Hospital, Gubbio, Italy.
Francesca PauroCystic Fibrosis Center, Azienda Opedaliera-Universitaria Integrata Di Verona, Verona, Italy.
Giovanna PisiCystic Fibrosis Center, Azienda Opedaliero-Universitaria di Parma, Parma, Italy.
Pietro RipaniUnità Operativa Semplice a Valenza Dipartimentale, Centro Regionale di Riferimento Fibrosi Cistica Regione Abruzzo ASL Teramo, P.O. San Liberatore, Atri, Italy.
Mirco RosCystic Fibrosis Support Center, Ospedale S. Maria Di Ca' Foncello, Treviso, Italy.
Novella RotoloCystic Fibrosis Center, Azienda Ospedaliera Universitaria Policlinico-San Marco-Catania, Catania, Italy.
Donatello SalvatoreCystic Fibrosis Center, Hospital San Carlo, Potenza, Italy.ORCID http://orcid.org/0000-0003-2432-415X
Angela SepePaediatric Unit, Department of Translational Medical Sciences, Cystic Fibrosis Regional Reference Center, University of Naples Federico II, Naples, Italy.
Lisa TerminiCystic Fibrosis Center, Ospedale Giovanni Di Cristina, Palermo, Italy.
Silviana TimpanoDepartment of Pediatrics, Cystic Fibrosis Regional Support Center, University of Brescia, ASST Spedali Civili Brescia, Brescia, Italy.
Patrizia TroianiCystic Fibrosis Regional Reference Center, A.O.U. Policlinico Umberto I, Rome, Italy.
Pamela VitulloCystic Fibrosis Support Center, Ospedale G. Tatarella di Cerignola, Cerignola, Italy.
Maurizio ZandaCystic Fibrosis Center, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Francesco BlasiDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milano, Italy.
Carlo CastellaniIRCCS Istituto Giannina Gaslini, Cystic Fibrosis Center, Genoa, Italy.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundNotwithstanding guidance from the European Cystic Fibrosis (CF) Society (ECFS) neonatal screening (NBS) working group, significant variation persists in the evaluation and management of Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) subjects, leaving many aspects of care under debate. This study reports the results of a national survey investigating management and treatment approaches of pre-school CFSPIDs in Italy.

methodsIn February 2024, a comprehensive questionnaire was distributed to all Italian CF centers. The survey explored various aspects of CFSPID management in the year 2023, including patient visit schedules, sweat tests (ST) timing, screening procedures, therapeutic interventions, and discharge criteria. Data on regional NBS protocols, number of CFSPID cases, and CF:CFSPID ratio were also collected.

resultsBy December 31, 2023, CF Italian centers were following 522 CFSPIDs. In 2023, CF NBS identified 85 CF and 68 CFSPID cases, resulting in a CF:CFSPID ratio of 1.25:1. Seven centers diagnosed more CFSPID than CF, with the lowest CF:CFSPID ratio being 0.20:1. A quarter of all centers reported management plans that deviated widely from ECFS guidelines. Respiratory cultures were performed in 16 (69.6%) centers in the absence of symptoms. Nine (38.9%) prescribed antibiotics in any case of positive Pseudomonas aeruginosa cultures, including first detections and asymptomatic subjects. Spirometries were performed by 14/23 centers (60.9%) in procedure-competent children at each visit. Follow up care continued after age 6 for all CFSPIDs in 15 (65.2%) centers regardless of age, genotype or ST results. A diagnosis of CF was established based on repeated pathological STs and/or multiorgan involvement. Children with STs in intermediate range and mono-organ involvement were classified as CFTR-related disorders (CFTR-RD).

conclusionsDespite available data on clinical course and recommendations on management of CFSPIDs, different approaches persist in clinical practice. Further efforts should be considered to disseminate and encourage adherence to international guidelines.

Indexed as

Cystic FibrosisNeonatal ScreeningChildChild, PreschoolFemaleHumansInfant, NewbornItalyMaleSurveys and QuestionnairesCFSPIDcystic fibrosisneonatal screeningoutcomessweat test

Identifiers

PMID39812351
PMCPMC11734379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.